Agios Pharmaceuticals (AGIO) Competitors

$27.73 -0.48 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$27.73 0.00 (0.00%)

As of 07:54 PM Eastern

AGIO vs. TGTX, MIRM, SYRE, RYTM, and PTGX

Should you buy Agios Pharmaceuticals stock or one of its competitors? MarketBeat compares Agios Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agios Pharmaceuticals include TG Therapeutics (TGTX), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Agios Pharmaceuticals compare to TG Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

58.6% of TG Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	30.52	-$412.78M	-$7.25	N/A
TG Therapeutics	$616.29M	9.79	$447.18M	$2.86	13.79

Agios Pharmaceuticals presently has a consensus price target of $41.56, indicating a potential upside of 49.86%. TG Therapeutics has a consensus price target of $52.50, indicating a potential upside of 33.15%. Given Agios Pharmaceuticals' higher possible upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 2 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.44 beat Agios Pharmaceuticals' score of 0.23 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has a net margin of 65.95% compared to Agios Pharmaceuticals' net margin of -639.84%. TG Therapeutics' return on equity of 88.73% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
TG Therapeutics	65.95%	88.73%	43.44%

Agios Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Summary

TG Therapeutics beats Agios Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Mirum Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.19	-$23.36M	-$13.61	N/A
Agios Pharmaceuticals	$54.03M	30.52	-$412.78M	-$7.25	N/A

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 5 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.32 beat Agios Pharmaceuticals' score of 0.23 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals currently has a consensus price target of $137.08, suggesting a potential upside of 43.31%. Agios Pharmaceuticals has a consensus price target of $41.56, suggesting a potential upside of 49.86%. Given Agios Pharmaceuticals' higher possible upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Agios Pharmaceuticals' net margin of -639.84%. Mirum Pharmaceuticals' return on equity of -11.28% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Summary

Mirum Pharmaceuticals beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Spyre Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	30.52	-$412.78M	-$7.25	N/A
Spyre Therapeutics	$890K	6,500.32	-$155.20M	-$2.08	N/A

Agios Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, suggesting that its stock price is 212% more volatile than the broader market.

Agios Pharmaceuticals presently has a consensus price target of $41.56, indicating a potential upside of 49.86%. Spyre Therapeutics has a consensus price target of $90.25, indicating a potential upside of 35.47%. Given Agios Pharmaceuticals' higher possible upside, research analysts clearly believe Agios Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.97 beat Agios Pharmaceuticals' score of 0.23 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Spyre Therapeutics	N/A	-42.88%	-27.76%

80.4% of Spyre Therapeutics shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Spyre Therapeutics beats Agios Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, indicating a potential upside of 51.14%. Agios Pharmaceuticals has a consensus target price of $41.56, indicating a potential upside of 49.86%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Rhythm Pharmaceuticals has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 9 mentions for Rhythm Pharmaceuticals and 5 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.23 beat Rhythm Pharmaceuticals' score of -0.47 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Rhythm Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.50	-$196.54M	-$3.13	N/A
Agios Pharmaceuticals	$54.03M	30.52	-$412.78M	-$7.25	N/A

Summary

Rhythm Pharmaceuticals beats Agios Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Protagonist Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	30.52	-$412.78M	-$7.25	N/A
Protagonist Therapeutics	$46.02M	137.47	-$130.15M	-$1.81	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has a net margin of -154.88% compared to Agios Pharmaceuticals' net margin of -639.84%. Protagonist Therapeutics' return on equity of -17.76% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Agios Pharmaceuticals currently has a consensus target price of $41.56, indicating a potential upside of 49.86%. Protagonist Therapeutics has a consensus target price of $113.69, indicating a potential upside of 15.58%. Given Agios Pharmaceuticals' higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

In the previous week, Agios Pharmaceuticals and Agios Pharmaceuticals both had 5 articles in the media. Protagonist Therapeutics' average media sentiment score of 0.59 beat Agios Pharmaceuticals' score of 0.23 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Agios Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.68B	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.27%
P/E Ratio	-3.82	18.52	20.79	25.04
Price / Sales	30.52	270.32	531.21	72.18
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	1.49	6.60	9.81	6.83
Net Income	-$412.78M	$24.18M	$3.55B	$335.69M
7 Day Performance	-2.43%	-3.56%	-2.07%	-2.03%
1 Month Performance	-21.09%	-7.86%	-3.90%	-1.90%
1 Year Performance	-7.07%	51.80%	29.39%	27.36%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	3.0142 of 5 stars	$27.73 -1.7%	$41.56 +49.9%	-3.3%	$1.68B	$54.03M	N/A	390
TGTX TG Therapeutics	4.132 of 5 stars	$43.14 +0.7%	$52.50 +21.7%	+14.9%	$6.56B	$616.29M	15.08	290
MIRM Mirum Pharmaceuticals	2.7904 of 5 stars	$106.17 -0.9%	$136.42 +28.5%	+112.2%	$6.53B	$521.31M	N/A	140	Analyst Forecast
SYRE Spyre Therapeutics	2.5366 of 5 stars	$76.43 +1.9%	$89.08 +16.6%	+361.7%	$6.52B	$890K	N/A	73
RYTM Rhythm Pharmaceuticals	2.2645 of 5 stars	$87.39 -7.2%	$131.81 +50.8%	+44.9%	$6.45B	$189.76M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. TGTX, MIRM, SYRE, RYTM, and PTGX

How does Agios Pharmaceuticals compare to TG Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. TGTX, MIRM, SYRE, RYTM, and PTGX

How does Agios Pharmaceuticals compare to TG Therapeutics?

Do insiders & institutionals believe in AGIO or TGTX?

Which has better earnings & valuation, AGIO or TGTX?

Do analysts recommend AGIO or TGTX?

Does the media refer more to AGIO or TGTX?

Is AGIO or TGTX more profitable?

Which has more risk & volatility, AGIO or TGTX?

Summary

How does Agios Pharmaceuticals compare to Mirum Pharmaceuticals?

Which has preferable valuation and earnings, MIRM or AGIO?

Does the media refer more to MIRM or AGIO?

Do analysts rate MIRM or AGIO?

Which has more risk and volatility, MIRM or AGIO?

Is MIRM or AGIO more profitable?

Summary

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Which has higher valuation and earnings, AGIO or SYRE?

Which has more risk & volatility, AGIO or SYRE?

Do analysts prefer AGIO or SYRE?

Does the media favor AGIO or SYRE?

Is AGIO or SYRE more profitable?

Do institutionals and insiders hold more shares of AGIO or SYRE?

Summary

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Do analysts prefer RYTM or AGIO?

Which has more risk and volatility, RYTM or AGIO?

Does the media favor RYTM or AGIO?

Is RYTM or AGIO more profitable?

Which has preferable valuation and earnings, RYTM or AGIO?

Summary

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Which has higher earnings and valuation, AGIO or PTGX?

Do institutionals and insiders believe in AGIO or PTGX?

Is AGIO or PTGX more profitable?

Do analysts rate AGIO or PTGX?

Which has more volatility and risk, AGIO or PTGX?

Does the media favor AGIO or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools